Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 4/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12184132 | 0.96 | PRCP (0.51) | PRCPGPBAR1HSD17B10MEN1KMT2A | |
| SCHEMBL14749414 | 0.92 | PRCP (0.51) | PRCPGPBAR1POLBMAPTMAPK1 | |
| SCHEMBL14749384 | 0.92 | PRCP (0.51) | PRCPGPBAR1HSD17B10POLBMAPK1 | |
| SCHEMBL14749316 | 0.86 | PRCP (0.57) | PRCPGPBAR1POLBMAPTMAPK1 | |
| SCHEMBL14749383 | 0.85 | PRCP (0.49) | PRCPEPHX2CYP2C9 | |
| SCHEMBL14736554 | 0.85 | PRCP (0.51) | PRCPGPBAR1POLBMAPTALDH1A1 | |
| SCHEMBL14749412 | 0.83 | PRCP (0.50) | PRCPMAPTMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14749396 | 0.83 | PRCP (0.51) | PRCPKMT2AALDH1A1EPHX2CYP2C9 | |
| SCHEMBL14749374 | 0.82 | PRCP (0.51) | PRCP | |
| SCHEMBL14749394 | 0.82 | PRCP (0.56) | PRCPMAPTKMT2AALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885GPBAR1 1882/4885HSD17B10 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.